Literature DB >> 24621081

Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.

A H E Herbers1, A F J de Haan, W J F M van der Velden, J P Donnelly, N M A Blijlevens.   

Abstract

BACKGROUND: In the 1960s, it was reported that infectious complications were the main cause of fever during neutropenia that followed hematopoietic stem cell transplant (HSCT). More recently, mucositis has become recognized as an important determinant of the inflammatory response and infectious complications.
METHODS: The objective of this prospective study was to determine the impact of intestinal mucositis, as measured by plasma citrulline, and neutropenia on the systemic inflammatory response (C-reactive protein) and the occurrence of bacteremia among 2 cohorts of HSCT recipients: 1 composed of 18 patients who had been treated with a myeloablative (MA) regimen (high-dose melphalan) and the other involving 19 patients who had received the non-myeloablative (NMA) regimen (fludarabine and cyclophosphamide). Blood cultures were obtained for surveillance from admission onwards as well as at the onset of fever.
RESULTS: The MA regimen induced severe intestinal mucositis manifest by citrullinemia <10 μmol/L, which was accompanied by an inflammatory response, and bacteremia affected 8 (44%) of 18 patients and coincided with the nadir of citrullinemia. By contrast, those who had been treated with the NMA regimen did not develop severe intestinal mucositis, had a moderate inflammatory response, and only 2 (11%) of the 19 patients developed bacteremia. However, both groups experienced profound neutropenia and its duration was significantly longer for those receiving the NMA regimen.
CONCLUSION: This study suggests that severe intestinal mucositis, i.e., citrullinemia <10 μmol/L, defines the period of risk of bacteremia better than does neutropenia, and that measuring plasma citrulline may prove useful in deciding who needs empirical antimicrobial therapy and when.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  citrulline; hematopoietic stem cell transplant; high-dose melphalan; infections; mucositis; reduced intensity

Mesh:

Substances:

Year:  2014        PMID: 24621081     DOI: 10.1111/tid.12195

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  20 in total

1.  Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.

Authors:  Tomoaki Ueda; Tomoyasu Jo; Kazuya Okada; Yasuyuki Arai; Takayuki Sato; Takeshi Maeda; Tatsuhito Onishi; Yasunori Ueda
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

2.  Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.

Authors:  Andreas F Widmer; Winfried V Kern; Jan A Roth; Markus Dettenkofer; Tim Goetting; Hartmut Bertz; Christian Theilacker
Journal:  Infection       Date:  2019-06-11       Impact factor: 3.553

Review 3.  Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

Authors:  Michal Kuczma; Zhi-Chun Ding; Gang Zhou
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 4.  Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?

Authors:  Lucy E Horton; Nina M Haste; Randy A Taplitz
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

Review 5.  Bloodstream infections in neutropenic cancer patients: A practical update.

Authors:  Giulia Gustinetti; Malgorzata Mikulska
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

6.  A Stromal Cell Niche for Human and Mouse Type 3 Innate Lymphoid Cells.

Authors:  Kerim Hoorweg; Priyanka Narang; Zhi Li; Anne Thuery; Natalie Papazian; David R Withers; Mark C Coles; Tom Cupedo
Journal:  J Immunol       Date:  2015-09-16       Impact factor: 5.422

7.  Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation.

Authors:  Rajat Bansal; Heekuk Park; Cristian C Taborda; Christian Gordillo; Markus Y Mapara; Amer Assal; Anne-Catrin Uhlemann; Ran Reshef
Journal:  Transplant Cell Ther       Date:  2021-12-24

8.  No effect of deleted in malignant brain tumors 1 deficiency on chemotherapy induced murine intestinal mucositis.

Authors:  Anders B Nexoe; Andreas A Pedersen; Sebastian von Huth; Grith L Sorensen; Uffe Holmskov; Ping-Ping Jiang; Sönke Detlefsen; Steffen Husby; Mathias Rathe
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

9.  Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.

Authors:  Albert Esquirol; Maria Jesús Pascual; Mi Kwon; Ariadna Pérez; Rocio Parody; Christelle Ferra; Irene Garcia Cadenas; Beatriz Herruzo; Nieves Dorado; Rafael Hernani; Isabel Sanchez-Ortega; Anna Torrent; Jorge Sierra; Rodrigo Martino
Journal:  Bone Marrow Transplant       Date:  2021-05-31       Impact factor: 5.483

10.  Successful treatment of sepsis due to Pantoea agglomerans by polymyxin B-immobilized fiber column direct hemoperfusion therapy in a small cell lung carcinoma patient.

Authors:  Hironobu Tsubouchi; Nobuhiro Matsumoto; Shigehisa Yanagi; Yasuji Arimura; Masamitsu Nakazato
Journal:  Respir Med Case Rep       Date:  2016-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.